Publikationen, an denen er mitarbeitet Andrés Íñiguez Romo (27)

2023

  1. Changes in circulating ApoJ-Glyc levels in patients with suspected acute coronary syndrome: The EDICA trial

    International Journal of Cardiology, Vol. 391

  2. Trends in cardiovascular care in the National Health System in Spain. Data from the RECALCAR project 2011-2020

    Revista Espanola de Cardiologia, Vol. 76, Núm. 7, pp. 519-530

2022

  1. Clinical Features and Long-Term Outcomes in Very Young Patients with Myocardial Infarction with Non-Obstructive Coronary Arteries

    Journal of Interventional Cardiology, Vol. 2022

2021

  1. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

    Journal of the American College of Cardiology, Vol. 78, Núm. 5, pp. 421-433

  2. Percutaneous and surgical aortic valve replacement. Impact of volume and type of center on results

    REC: Interventional Cardiology, Vol. 3, Núm. 2, pp. 103-111

  3. Reemplazo valvular aórtico percutáneo y quirúrgico.: Influencia del volumen y del tipo de centro tratante en los resultados

    REC: Interventional Cardiology, Vol. 3, Núm. 2, pp. 103-111

  4. TAVI en la curva de aprendizaje en España. Resultados intrahospitalarios comparados con la sustitución valvular aórtica

    REC: CardioClinics, Vol. 56, Núm. 4, pp. 242-249

  5. TAVI in the learning curve in Spain. In-hospital results compared with aortic valve replacement

    REC: CardioClinics, Vol. 56, Núm. 4, pp. 242-249

2020

  1. Incidence, predictors and prognostic impact of intracranial bleeding within the first year after an acute coronary syndrome in patients treated with percutaneous coronary intervention

    European Heart Journal: Acute Cardiovascular Care, Vol. 9, Núm. 7, pp. 764-770

  2. P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects

    European heart journal. Cardiovascular pharmacotherapy, Vol. 6, Núm. 1, pp. 31-42

2019

  1. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628

  2. Management of myocardial infarction in the elderly. Insights from Spanish Minimum Basic Data Set

    European Heart Journal: Acute Cardiovascular Care, Vol. 8, Núm. 3, pp. 242-251

2018

  1. Alirocumab and cardiovascular outcomes after acute coronary syndrome

    New England Journal of Medicine, Vol. 379, Núm. 22, pp. 2097-2107

  2. Development and external validation of a post-discharge bleeding risk score in patients with acute coronary syndrome: The BleeMACS score

    International Journal of Cardiology, Vol. 254, pp. 10-15

  3. Patterns of Inpatient Care and Readmission Rates (30-day, 3-month and 1-year) in Myocardial Infarction in Spain. Differences Between STEMI and NSTEMI

    Revista Espanola de Cardiologia, Vol. 71, Núm. 9, pp. 757-758

  4. Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry

    Indian Heart Journal, Vol. 70, Núm. 6, pp. 828-835

2017

  1. Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention

    Journal of the American College of Cardiology, Vol. 69, Núm. 2, pp. 176-185

  2. Evolocumab and clinical outcomes in patients with cardiovascular disease

    New England Journal of Medicine, Vol. 376, Núm. 18, pp. 1713-1722

  3. Impacto en la mortalidad de diferentes sistemas de asistencia en red para el tratamiento del infarto agudo de miocardio con elevación del segmento ST. La experiencia de España

    Revista Espanola de Cardiologia, Vol. 70, Núm. 3, pp. 155-161

  4. Patterns of inpatient care for acute myocardial infarction and 30-day, 3-month and 1-year cardiac diseases readmission rates in Spain

    International Journal of Cardiology, Vol. 230, pp. 14-20